PK model [Regulatives / Guidelines]

posted by PharmCat  – Russia, 2020-09-10 20:12 (707 d 00:46 ago) – Posting: # 21915
Views: 2,482

Hi Helmut!

I can be wrong.

I suppose when we have modified release dosage form there are can be some changes in the PK model. We shold take in to accaunt that dissolution profile of form in GI can have own dynamic. For example: if absorbtion of dissoluted drug is high and dissolution is linear we can have something with "plato" profile. So resulting PK profile can be wery surprising.

Complete thread:

UA Flag
Activity
 Admin contact
22,305 posts in 4,668 threads, 1,587 registered users;
online 5 (0 registered, 5 guests [including 1 identified bots]).
Forum time: Thursday 20:58 CEST (Europe/Vienna)

On two occasions I have been asked,—“Pray, Mr. Babbage,
if you put into the machine wrong figures,…
will the right answers come out?”
 …
I am not able rightly to apprehend the kind of confusion of ideas
that could provoke such a question.    Charles Babbage

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5